{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:08:18Z","timestamp":1789470498955,"version":"build-2803163510"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.jsat.2019.10.003","type":"journal-article","created":{"date-parts":[[2019,10,20]],"date-time":"2019-10-20T17:07:30Z","timestamp":1571591250000},"page":"38-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Adjunctive memantine for opioid use disorder treatment: A systematic review"],"prefix":"10.1016","volume":"107","author":[{"given":"Allison M.","family":"Elias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2019.10.003_bb0005","series-title":"Trends in the use of methadone, buprenorphine, and extended-release naltrexone at substance abuse treatment facilities: 2003\u20132015 (update)","author":"Alderks","year":"2017"},{"key":"10.1016\/j.jsat.2019.10.003_bb0010","series-title":"Diagnostic and statistical manual of mental disorders","article-title":"Opioid Use Disorder","author":"American Psychiatric Association","year":"2013"},{"issue":"17","key":"10.1016\/j.jsat.2019.10.003_bb0015","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1080\/14656566.2016.1244529","article-title":"Update on pharmacotherapy for treatment of opioid use disorder","volume":"17","author":"Ayanga","year":"2016","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.jsat.2019.10.003_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s002130100739","article-title":"The NMDA antagonist memantine attenuates the expression of opioid physical dependence in humans","volume":"157","author":"Bisaga","year":"2001","journal-title":"Psychopharmacology"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2019.10.003_bb0025","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.drugalcdep.2011.05.019","article-title":"A placebo controlled trial of memantine as an adjunct to oral naltrexone for opioid dependence","volume":"119","author":"Bisaga","year":"2011","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2019.10.003_bb0030","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jsat.2014.01.005","article-title":"A placebo-controlled trial of memantine as an adjunct to injectable extended-release naltrexone for opioid dependence","volume":"46","author":"Bisaga","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2019.10.003_bb0035","author":"CDC, National Center for Health Statistics"},{"key":"10.1016\/j.jsat.2019.10.003_bb0040","doi-asserted-by":"crossref","first-page":"9708","DOI":"10.1038\/srep09708","article-title":"Low-dose add-on memantine treatment may improve cognitive performance and self-reported health conditions in opioid-dependent patients undergoing methadone-maintenance-therapy","volume":"5","author":"Chang","year":"2015","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.jsat.2019.10.003_bb0045","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s11481-011-9337-9","article-title":"Low-dose memantine attenuated morphine addictive behavior through its anti-inflammation and neurotrophic effects in rats","volume":"7","author":"Chen","year":"2012","journal-title":"Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology"},{"issue":"2","key":"10.1016\/j.jsat.2019.10.003_bb0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00213-007-0775-2","article-title":"Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers","volume":"193","author":"Comer","year":"2007","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.jsat.2019.10.003_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"issue":"3","key":"10.1016\/j.jsat.2019.10.003_bb0060","first-page":"330","article-title":"Memantine hydrochloride to assist with opioid rotation from methadone","volume":"26","author":"Denio","year":"2013","journal-title":"Journal of Pharmacy Practice"},{"key":"10.1016\/j.jsat.2019.10.003_bb0065","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1016\/j.drugalcdep.2014.09.256","article-title":"Memantine improves buprenorphine treatment for opioid-dependent young adults","volume":"146","author":"Gonzalez","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.10.003_bb0070","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drugalcdep.2015.09.020","article-title":"Memantine improves buprenorphine\/naloxone treatment for opioid dependent young adults","volume":"156","author":"Gonzalez","year":"2015","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2019.10.003_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"1","key":"10.1016\/j.jsat.2019.10.003_bb0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5055\/jom.2011.0044","article-title":"A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts","volume":"7","author":"Jain","year":"2011","journal-title":"Journal of Opioid Management"},{"issue":"1","key":"10.1016\/j.jsat.2019.10.003_bb0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1517\/14740330802528420","article-title":"Memantine: A comprehensive review of safety and efficacy","volume":"8","author":"Kavirajan","year":"2009","journal-title":"Expert Opinion on Drug Safety"},{"key":"10.1016\/j.jsat.2019.10.003_bb0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/00132576-200211000-00006","article-title":"A pilot study of memantine effects on protracted withdrawal (syndrome of anhedonia) in heroin addicts","volume":"1","author":"Krupitsky","year":"2002","journal-title":"Addict Disord Their Treatment"},{"key":"10.1016\/j.jsat.2019.10.003_bb0095","doi-asserted-by":"crossref","first-page":"10140","DOI":"10.1038\/srep10140","article-title":"Low-dose memantine attenuated methadone dose in opioid-dependent patients: A 12-week double-blind randomized controlled trial","volume":"5","author":"Lee","year":"2015","journal-title":"Scientific Reports"},{"key":"10.1016\/j.jsat.2019.10.003_bb0100","unstructured":"Lexi-Drugs. Lexicomp. (2019). Wolters Kluwer Health, Inc. Hudson, OH. Available at: http:\/\/online.lexi.com. ."},{"issue":"4","key":"10.1016\/j.jsat.2019.10.003_bb0105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1080\/15360288.2016.1241334","article-title":"Memantine for the treatment of phantom limb pain: A systematic review","volume":"30","author":"Loy","year":"2016","journal-title":"Journal of Pain & Palliative Care Pharmacotherapy"},{"key":"10.1016\/j.jsat.2019.10.003_bb0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Annals of Internal Medicine"},{"key":"10.1016\/j.jsat.2019.10.003_bb0115","unstructured":"Namenda [package insert]. (2013). St. Louis, MO: Forest Pharmaceuticals, Inc. Retrieved from https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=b9f27baf-aa2a-443a-9ef5-e002d23407ba. ."},{"key":"10.1016\/j.jsat.2019.10.003_bb0120","author":"National Institute on Drug Abuse"},{"issue":"1","key":"10.1016\/j.jsat.2019.10.003_bb0125","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.npp.1300760","article-title":"Reinstatement of morphine-conditioned reward is blocked by memantine","volume":"31","author":"Popik","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/j.jsat.2019.10.003_bb0130","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3390\/ph6020251","article-title":"NMDA receptor modulators in the treatment of drug addiction","volume":"6","author":"Tomek","year":"2013","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219303034?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219303034?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:50:16Z","timestamp":1760039416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547219303034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":26,"alternative-id":["S0740547219303034"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2019.10.003","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjunctive memantine for opioid use disorder treatment: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2019.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}